AZ Targets Viral Oncolytics With Transgene Development Deal
AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.
You may also be interested in...
The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.
Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.
Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.